Biogen (BIIB) Could Be 9% Undervalued As Pipeline Hopes Shape The Valuation

Biogen Stock Performance Snapshot

Biogen (BIIB) has drawn investor attention after a period of mixed long term returns, with the stock showing a 0.6% move over the past week and a month return of 3.0% heading into late June 2026.

See our latest analysis for Biogen.

Looking beyond the recent moves, Biogen’s 12.2% year to date share price return, alongside a 56.8% total shareholder return over the past year but weaker multi year total returns, suggests momentum has picked up recently after a tougher stretch for long term holders.

If you are comparing Biogen with other potential opportunities in healthcare, this could be a good moment to see what is happening across specialist biotech and 38 healthcare AI stocks

With Biogen trading at $199.59, carrying a value score of 4 and a modelled intrinsic discount of 52.8%, investors are left asking whether this is a genuine mispricing or if the market is already factoring in future growth.

Most Popular Narrative: 9% Undervalued

Based on the most widely followed narrative, Biogen’s fair value of $219.27 sits above the current $199.59 share price, which frames the stock as undervalued in that model.

Robust late stage and diversified neurodegenerative and specialty disease pipelines including Phase III launches in SMA, lupus, and kidney indications capitalize on regulatory momentum to address high unmet needs, creating multiple shots on goal that reduce future revenue volatility and support long term earnings stability.

Read the complete narrative.

Curious what kind of revenue profile, margin uplift, and future earnings power this narrative is baking in, and how those inputs tie back to that higher fair value estimate.

Result: Fair Value of $219.27 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Biogen’s story also carries execution risks, including pressure on its multiple sclerosis franchise and uncertainty around newer launches like LEQEMBI and ZURZUVAE as they work to gain traction.

Find out about the key risks to this Biogen narrative.

Another View on Biogen’s Valuation

The first narrative frames Biogen as undervalued using analyst fair value estimates, but the earnings multiple tells a more mixed story. Biogen trades on a P/E of 21.5x, above the US Biotechs industry at 16.7x, yet below peers at 26.9x and close to a fair ratio of 23.1x. This raises the question of whether that points to limited upside or room for the market to close the gap.

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With mixed signals across Biogen’s momentum and valuation, are you leaning bullish or cautious, and how quickly do you want to firm up that view? To balance the 1 or more risks investors are watching against the 1 or more rewards they are optimistic about, review the 2 key rewards and 1 important warning sign

Looking for more investment ideas beyond Biogen?

If Biogen has sharpened your focus on opportunities in healthcare, do not stop here. Broaden your watchlist with a few targeted sets of stocks right now.

• Target potential mispricings by scanning a curated group of companies that appear attractively valued using the 44 high quality undervalued stocks.
• Prioritize resilience by reviewing businesses that currently feature in the 69 resilient stocks with low risk scores.
• Hunt for future standouts before they hit the spotlight by checking the screener containing 18 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com